Here are the slides for the San Diego Clinical Research Network + San Diego Regulatory Affairs Network program on May 9. Clinical Trials in the Future. How Mobile Technologies and Telemedicine are Transforming Clinical Research.
UNLOCKING ACCESS: HOW MOBILE TECHNOLOGY ACCELERATES DISCOVERY
Kevin Bruhn, Ph.D., VP, Strategic Development, Science 37
The industry pipeline of hope for new treatments continues to be slow and expensive. Despite clinical trials being the next best treatment option in some disease like cancer, the clinical trial participation rate remains very low. Of the many hurdles to participation, geographic access is the biggest challenge. Many patients do not live near the trial centers. Technology has led to the re-imagination of so many industries like entertainment, transportation and even a highly regulated industry like banking. Science 37 has used telemedicine and mobile health technologies to transform the clinical trial model by shifting the center for research from traditional academic investigative sites to the patient’s home and local healthcare system. Science 37’s novel platform unlocks access to clinical trials for a larger, more diverse patient population resulting in accelerated drug development.
MHEALTH – WHERE IT HAS BEEN AND WHERE IS IT GOING? (click here for slides)
Kim Tyrrell-Knott, J.D.
The life science industry is going through incredible change and disruption, and so is the regulatory environment. Mobile devices and wearables are ubiquitous. Applications that support clinical decisions making are readily available for consumers, patients, and healthcare providers. Drugs and other therapies are leveraging data and technologies to facilitate patient engagement and adherence. Regulators in the U.S. and around the world are struggling with how to best regulate novel technologies without stifling innovation, and enabling patients and providers access to these advancements. This presentation will discuss the current regulatory framework, its benefits, challenges, and the work that is still left to be done.
Leave a Reply